Brought to you by 
Arena grants Ildong exclusive rights to Belviq in South Korea
17 Jan 2017
Executive Summary
Arena Pharmaceuticals Inc.’s wholly owned subsidiary Arena Pharmaceuticals GMBH has licensed Ildong Pharmaceutical Co. Ltd. exclusive rights to market and distribute the weight loss drug Belviq (lorcaserin) in its home country of South Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arena grants Ildong exclusive rights to Belviq in South Korea
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice